TITLE

Trastuzumab

PUB. DATE
November 2009
SOURCE
Reactions Weekly;11/14/2009, Issue 1278, p29
SOURCE TYPE
Periodical
DOC. TYPE
Case Study
ABSTRACT
The article describes the case of a woman who developed thrombocytopenia while receiving trastuzumab-based adjuvant chemotherapy for breast cancer. The patient experienced a decreased platelet count but returned to normal after treatment with corticosteroids. Her chemotherapy consists of docetaxel and trastuzumab.
ACCESSION #
45226698

 

Related Articles

  • Neoadjuvant THP economically favourable in US.  // PharmacoEconomics & Outcomes News;Jun2014, Vol. 705 Issue 1, p8 

    The article reports on a 2014 study in the U.S. showing that pertuzumab + trastuzumab + docetaxel (THP) is the most cost-effective neoadjuvant treatment of HER2-positive locally advanced, inflammatory or early breast cancer.

  • Precision medicine and personalized breast cancer: combination pertuzumab therapy. Reynolds, Kerry; Sarangi, Sasmit; Bardia, Aditya; Dizon, Don S. // Pharmacogenomics & Personalized Medicine;2014, Vol. 7, p95 

    Trastuzumab (Herceptin), a monoclonal antibody directed against the human epidermal growth-factor receptor 2 (HER2), is the poster child for antibody-based targeted therapy in breast cancer. Pertuzumab, another humanized monoclonal antibody, binds to a different domain of HER2 and prevents the...

  • Cardiac risk in the treatment of breast cancer: assessment and management. Valachis, Antonis; Nilsson, Cecilia // Breast Cancer: Targets & Therapy;2015, Vol. 7, p21 

    As the number of long-term breast cancer survivors has increased, the side effects of adjuvant cancer therapy, such as cardiac toxicity, remain clinically important. Although the cardiac toxicity due to anthracyclines, radiotherapy, or trastuzumab is well-documented, several issues need to be...

  • Optimal treatment of early stage HER2-positive breast cancer. Pernas, Sonia; Barroso‐Sousa, Romualdo; Tolaney, Sara M.; Barroso-Sousa, Romualdo // Cancer (0008543X);Dec2018, Vol. 124 Issue 23, p4455 

    Significant advances have occurred in the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer that have changed its natural history. The addition of trastuzumab to standard therapy has dramatically improved the prognosis for patients with early stage,...

  • Docetaxel.  // Reactions Weekly;03/01/2013, Issue 1441, p14 

    The article presents a case study of a 60-year-old woman who developed neutropenic enterocolitis while receiving docetaxel to treat breast cancer.

  • National Institute of Health Consensus Development Conference Statement: Adjuvant Therapy for....  // JNCI: Journal of the National Cancer Institute;7/14/2001, Vol. 93 Issue 13, p979 

    Focuses on the conference statement on the use of adjuvant therapy for breast cancer in the United States. Aims of the National Institutes of Health Consensus Development conference; Availability of adjuvant therapy to women with tumors expressing hormone receptor protein; Inclusion of...

  • Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Swain, S. M.; Baselga, J.; Miles, D.; Im, Y.-H.; Quah, C.; Lee, L. F.; Cortés, J. // Annals of Oncology;Jun2014, Vol. 25 Issue 6, p1116 

    This manuscript presents exploratory analyses of the incidence and time to development of CNS metastases in patients with first-line HER2-positive metastatic breast cancer in the CLEOPATRA study of pertuzumab, trastuzumab, and docetaxel. The results showed that pertuzumab, trastuzumab, and...

  • Pertuzumab for First-Line Treatment of HER2+ Advanced Breast Cancer: Where Does It Fit? Pieńkowski, Tadeusz // Journal of OncoPathology;Jun2014, Vol. 2 Issue 2, p25 

    The human epidermal growth factor receptor II (HER2) plays an important role in the development of breast cancer. Targeting HER2 with monoclonal antibodies drastically improved treatment outcomes in breast cancer patients with HER2 overexpression. Four anti-HER agents used in clinical practice:...

  • Risk of febrile neutropenia in patients receiving emerging chemotherapy regimens for breast cancer. Gilbar, Peter; Sorour, Natacha; McPherson, Ian // Supportive Care in Cancer;Mar2015, Vol. 23 Issue 3, p619 

    A letter to the editor about the risk of febrile neutropenia (FN) with the docetaxel + cyclophosphamide (TC) and docetaxel + carboplatin + trastuzumab (TCH) regimens for breast cancer is presented.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics